Comparable stake leader
BlackRock, Inc.
SEC ownership of PTC THERAPEUTICS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001070081.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
09 Jul 2026
- Public ticker
- PTCT on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
09 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001070081
- Issuer location
- Warren, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of PTC THERAPEUTICS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
09 Jul 2026
13F
13D/G
3/4/5
Lead comparable stake: 15%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 15%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
15%
Janus Henderson Group Ltd.
8.7%
ARMISTICE CAPITAL, LLC
6.9%
VANGUARD PORTFOLIO MANAGEMENT LLC
5.9%
STATE STREET CORP
5.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
15%
from 13D/G
|
$1,139,088,671
13,964,554 shares
|
— | 30 Jun 2026 |
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
8.7%
|
$494,116,913
7,193,433 shares
|
+$160,878,918 | 31 Mar 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
13F
Company
|
6.9%
|
$269,133,425
5,434,843 shares
|
-$46,705,135 | 31 Mar 2025 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
13D/G
Company · Vanguard Portfolio Management
|
5.9%
from 13D/G
|
$401,986,014
4,928,111 shares
|
— | 30 Jun 2026 |
| STATE STREET CORP |
13F
13D/G
Company · STATE STREET CORPORATION
|
5.2%
from 13D/G
|
$375,136,515
4,598,952 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
13D/G
Company · Vanguard Capital Management
|
5.2%
from 13D/G
|
$305,000,589
3,739,127 shares
|
— | 30 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
13D/G
Company
|
4.8%
from 13D/G
|
$336,743,228
4,128,273 shares
|
— | 30 Jun 2026 |
| Camber Capital Management LP |
13D/G
|
4.2%
|
$158,464,000
3,200,000 shares
|
$0 | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$68,668,985.
Buys
$0
Insiders: 0
Sells
$68,668,985
Insiders: 14
Net
-$68,668,985
Shares: -934,097
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 934,097
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 246,337 | $0 | $19,750,658 | -$19,750,658 |
| 3-6 | 0 | 94,700 | $0 | $6,637,946 | -$6,637,946 |
| 6-9 | 0 | 183,926 | $0 | $13,576,808 | -$13,576,808 |
| 9-12 | 0 | 409,134 | $0 | $28,703,572 | -$28,703,572 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 22 reporting-owner rows connected to PTC THERAPEUTICS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
22
Largest Forms 3/4/5 holder
Michael Schmertzler
Net 12M change
-$68,668,984
Latest report
26 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Michael Schmertzler | Director | $110,322,505 | -$3,611,921 | -3.2% | Mixed | 26 Aug 2026 |
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER, Director | $31,055,578 | -$4,219,886 | -12% | Mixed | 04 Aug 2026 |
| Stuart Walter Peltz | CHIEF EXECUTIVE OFFICER, Director | $10,876,127 | Mixed | 31 Jan 2023 | ||
| Pierre Gravier | Chief Financial Officer | $8,269,838 | -$652,864 | -7.3% | Mixed | 14 Jul 2026 |
| Mark Elliott Boulding | Exec. Vp And Clo | $7,674,328 | -$8,846,136 | -54% | Filing P/S | 17 Aug 2026 |
| Eric Pauwels | Chief Business Officer | $6,993,575 | -$9,745,534 | -58% | Mixed | 10 Jun 2026 |
| Neil Gregory Almstead | Chief Technical Ops Officer | $6,963,339 | -$25,989,289 | -79% | Mixed | 09 Jul 2026 |
| Lee Scott Golden | Evp & Chief Medical Officer | $6,731,528 | -$1,081,515 | -14% | Mixed | 02 Apr 2026 |
| Christine Marie Utter | Svp, Chief Accounting Officer | $6,250,986 | -$1,941,426 | -24% | Mixed | 17 Jun 2026 |
| Elisabeth Sollie Zetlmayer | Director | $4,284,545 | Median | 28 Jul 2026 | ||
| Mary L. Smith | Director | $2,201,210 | -$1,425,060 | -39% | Mixed | 09 Jul 2026 |
| Jerome B. Zeldis | Director | $1,947,140 | Mixed | 02 Jan 2026 | ||
| Glenn Jr. MD Steele PhD | Director | $1,947,140 | -$916,200 | -32% | Mixed | 02 Jan 2026 |
| Allan Steven Jacobson | Director | $1,867,457 | -$2,912,018 | -61% | Mixed | 02 Jan 2026 |
| Alethia Young | Director | $1,838,289 | Mixed | 02 Jan 2026 | ||
| David P. Southwell | Director | $1,821,806 | -$700,080 | -28% | Mixed | 02 Jan 2026 |
| Emily Luisa Hill | Chief Financial Officer | $1,065,782 | Mixed | 27 Mar 2023 | ||
| Emma Reeve | Director | $1,048,656 | -$5,163,979 | -83% | Mixed | 02 Jan 2026 |
| Stephanie Okey | Director | $798,040 | -$1,463,076 | -65% | Mixed | 10 Mar 2026 |
| Dawn Svoronos | Director | $794,497 | Mixed | 09 Jun 2022 |
Recent insider transactions for PTC THERAPEUTICS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Michael Schmertzler | PTCT | Common Stock | Sale | -0.93% | $894,784 | $71.58 | -12,500 | 1,336,594 | 27 Aug 2026 | See footnote |
| Michael Schmertzler | PTCT | Common Stock | Sale | -0.92% | $911,725 | $72.94 | -12,500 | 1,349,094 | 26 Aug 2026 | See footnote |
| Michael Schmertzler | PTCT | Common Stock | Sale | -0.91% | $888,858 | $71.11 | -12,500 | 1,361,594 | 20 Aug 2026 | See footnote |
| Michael Schmertzler | PTCT | Common Stock | Sale | -0.9% | $916,554 | $73.32 | -12,500 | 1,374,094 | 19 Aug 2026 | See footnote |
| Mark Elliott Boulding | PTCT | Common Stock | Sale | -2.6% | $204,127 | $72.57 | -2,813 | 105,272 | 17 Aug 2026 | Direct |
| Mark Elliott Boulding | PTCT | Common Stock | Options Exercise | 2.67% | 2,813 | 108,085 | 17 Aug 2026 | Direct | ||
| Mark Elliott Boulding | PTCT | Stock Option (Right to Buy) | Options Exercise | -14.3% | -2,813 | 16,876 | 17 Aug 2026 | Direct | ||
| Matthew B. Klein | PTCT | Common Stock | Sale | -2.61% | $705,722 | $68.57 | -10,292 | 383,868 | 04 Aug 2026 | Direct |
| Elisabeth Sollie Zetlmayer | PTCT | Common Stock | Award | 12.9% | 6,000 | 52,526 | 28 Jul 2026 | Direct | ||
| Elisabeth Sollie Zetlmayer | PTCT | Stock Option (Right to Buy) | Award | 5,213 | 3,475 | 28 Jul 2026 | Direct | |||
| Pierre Gravier | PTCT | Common Stock | Sale | -3.99% | $280,743 | $80.35 | -3,494 | 83,986 | 14 Jul 2026 | Direct |
| Mary L. Smith | PTCT | Common Stock | Sale | -42.1% | $1,425,060 | $90.00 | -15,834 | 21,813 | 09 Jul 2026 | Direct |
| Mary L. Smith | PTCT | Common Stock | Options Exercise | 99.1% | 15,834 | 31,813 | 09 Jul 2026 | Direct | ||
| Mary L. Smith | PTCT | Stock Option (Right to Buy) | Options Exercise | -100% | -15,834 | 0 | 09 Jul 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Common Stock | Sale | -3.93% | $222,376 | $90.25 | -2,464 | 60,299 | 09 Jul 2026 | Direct |
| Neil Gregory Almstead | PTCT | Common Stock | Options Exercise | 4.09% | 2,464 | 62,763 | 09 Jul 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Stock Option (Right to Buy) | Options Exercise | -5.19% | -2,464 | 45,036 | 09 Jul 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Common Stock | Sale | -29% | $2,187,745 | $88.89 | -24,613 | 60,299 | 07 Jul 2026 | Direct |
| Neil Gregory Almstead | PTCT | Common Stock | Options Exercise | 40.8% | 24,613 | 84,912 | 07 Jul 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Stock Option (Right to Buy) | Options Exercise | -73.1% | -24,613 | 9,063 | 07 Jul 2026 | Direct | ||
| Mark Elliott Boulding | PTCT | Common Stock | Sale | -4.6% | $432,118 | $85.08 | -5,079 | 105,272 | 06 Jul 2026 | Direct |
| Mark Elliott Boulding | PTCT | Common Stock | Options Exercise | 4.93% | 5,079 | 108,085 | 06 Jul 2026 | Direct | ||
| Mark Elliott Boulding | PTCT | Stock Option (Right to Buy) | Options Exercise | -52.6% | -5,039 | 4,532 | 06 Jul 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Common Stock | Sale | -26.9% | $1,905,736 | $86.00 | -22,161 | 60,299 | 06 Jul 2026 | Direct |
| Neil Gregory Almstead | PTCT | Common Stock | Options Exercise | 38.9% | 22,161 | 79,175 | 06 Jul 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Stock Option (Right to Buy) | Options Exercise | -100% | -22,161 | 0 | 06 Jul 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Common Stock | Sale | -11.9% | $693,151 | $85.26 | -8,130 | 60,137 | 26 Jun 2026 | Direct |
| Neil Gregory Almstead | PTCT | Common Stock | Options Exercise | 13.6% | 8,130 | 67,855 | 26 Jun 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Stock Option (Right to Buy) | Options Exercise | -29.2% | -8,130 | 19,687 | 26 Jun 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Common Stock | Sale | -25.8% | $1,801,857 | $85.97 | -20,960 | 60,137 | 25 Jun 2026 | Direct |
| Neil Gregory Almstead | PTCT | Common Stock | Options Exercise | 35.5% | 20,960 | 79,996 | 25 Jun 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Stock Option (Right to Buy) | Options Exercise | -43% | -20,960 | 27,817 | 25 Jun 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Common Stock | Sale | -8.13% | $452,607 | $85.03 | -5,323 | 60,137 | 24 Jun 2026 | Direct |
| Neil Gregory Almstead | PTCT | Common Stock | Options Exercise | 8.91% | 5,323 | 65,059 | 24 Jun 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Stock Option (Right to Buy) | Options Exercise | -9.86% | -5,323 | 48,677 | 24 Jun 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Common Stock | Sale | -28.3% | $1,921,378 | $80.90 | -23,749 | 60,137 | 22 Jun 2026 | Direct |
| Neil Gregory Almstead | PTCT | Common Stock | Options Exercise | 39.5% | 23,749 | 83,886 | 22 Jun 2026 | Direct | ||
| Neil Gregory Almstead | PTCT | Stock Option (Right to Buy) | Options Exercise | -50% | -23,749 | 23,751 | 22 Jun 2026 | Direct | ||
| Christine Marie Utter | PTCT | Common Stock | Sale | -21.9% | $1,487,474 | $75.56 | -19,686 | 70,199 | 17 Jun 2026 | Direct |
| Christine Marie Utter | PTCT | Common Stock | Options Exercise | 28% | 19,686 | 89,885 | 17 Jun 2026 | Direct | ||
| Christine Marie Utter | PTCT | Stock Option (Right to Buy) | Options Exercise | -56.2% | -19,686 | 15,314 | 17 Jun 2026 | Direct | ||
| Mark Elliott Boulding | PTCT | Common Stock | Sale | -9.04% | $822,868 | $78.65 | -10,462 | 105,272 | 17 Jun 2026 | Direct |
| Mark Elliott Boulding | PTCT | Common Stock | Options Exercise | 10.2% | 10,522 | 113,722 | 17 Jun 2026 | Direct | ||
| Mark Elliott Boulding | PTCT | Stock Option (Right to Buy) | Options Exercise | -25.4% | -10,522 | 30,938 | 17 Jun 2026 | Direct | ||
| Eric Pauwels | PTCT | Common Stock | Options Exercise | 23.9% | 17,566 | 90,977 | 10 Jun 2026 | Direct | ||
| Eric Pauwels | PTCT | Common Stock | Sale | -22.5% | $1,595,775 | $75.00 | -21,277 | 73,411 | 10 Jun 2026 | Direct |
| Eric Pauwels | PTCT | Stock Option (Right to Buy) | Sale | -100% | -17,566 | 0 | 10 Jun 2026 | Direct | ||
| Mark Elliott Boulding | PTCT | Common Stock | Sale | -2.6% | $202,958 | $72.18 | -2,812 | 105,212 | 15 May 2026 | Direct |
| Mark Elliott Boulding | PTCT | Common Stock | Options Exercise | 2.67% | 2,812 | 108,024 | 15 May 2026 | Direct | ||
| Mark Elliott Boulding | PTCT | Stock Option (Right to Buy) | Options Exercise | -12.5% | -2,812 | 19,689 | 15 May 2026 | Direct |
* marks a reported price that did not pass the local price check.